James A. Underberg (0000-0002-6615-8535)

Personal information

Biography

Dr. Underberg is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is the Director of the Bellevue Hospital Lipid Clinic.
Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology, a Fellow of the National Lipid Association and President of the Northeast Chapter of the National Lipid Association. He serves on the editorial board of the Journal of Clinical Lipidology and is a He is a board member of the National Lipid Association, the Foundation of the National Lipid Association and the American Board of Clinical Lipidology. Dr Underberg also serves on the scientific advisory board of the FH Foundation.
Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders, hypertension management and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology.
He sees patients both at Bellevue Hosptial and in a University based Private practice setting.

Activities

Collapse all

NYU School of Medicine: New York, NY, US

1987-07-01 to present | Clinical Assistant Professor of Medicine (Academic) (Medicine)

Employment

James A. Underberg

https://orcid.org/0000-0002-6615-8535

Personal information

Websites & social links

Keywords

Biography

Activities

Employment (1)

NYU School of Medicine: New York, NY, US

Education and qualifications (5)

New York University Langone Medical Center: New York, NY, US

Bellevue Hospital Center: New York, NY, US

University of Pennsylvania Perelman School of Medicine: Philadelphia, PA, US

Yale University: New Haven, CT, US

Yale University: New Haven, CT, US

Works (49)

LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals

A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE‐IT Study

Jcl Roundtable: Global Think Tank on Lipoprotein(a)

New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?

Long-term Safety and Efficacy of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Five-year Data from the Lomitapide Observational Worldwide Evaluation Registry (lower)

Characterization of Pcsk9 in the Blood and Skin of Psoriasis

Genetic Testing in Dyslipidemia: a Scientific Statement from the National Lipid Association

Longitudinal Low Density Lipoprotein Cholesterol Goal Achievement and Cardiovascular Outcomes Among Adult Patients with Familial Hypercholesterolemia: the Cascade Fh Registry

Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease

Lowering Ldl-cholesterol and Cv Benefits: is There a Limit to How Low Ldl-c Needs to Be for Optimal Health Benefits?

Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (impact) Trial

Long-termliver Safety of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-year Data from the Lomitapide Observational Worldwide Evaluation Registry (lower)

Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (impact) Trial

What is Sufficient Drug Therapy for Lipoprotein Elevations?

Health Disparities Among Adult Patients with a Phenotypic Diagnosis of Familial Hypercholesterolemia in the Cascade-fh Patient Registry

The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis

Genetic Effects on Efficacy of Lipid-lowering Drugs

Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Pcsk9 Inhibitor Therapeutics

Lipoprotein(a) Screening in Patients with Controlled Traditional Risk Factors Undergoing Percutaneous Coronary Intervention

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels

PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers

LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design

JCL roundtable: Risk evaluation and mitigation strategy

Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Cardiovascular Effects of the New Weight Loss Agents

Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?

Diagnosing familial hypercholesterolemia (FH) in the United States: Results from the cascade FH patient registry

Lomitapide observational worldwide evaluation registry (LOWER): One-year data

Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention

The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines?

Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir

Laparoscopic gastric banding resolves the metabolic syndrome and improves lipid profile over five years in obese patients with body mass index 30–40 kg/m2

Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention

Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry

Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop

New Treatment Approaches for Dyslipidemia and its Management

Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values

Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic Patients

Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management

Utility of different lipid measures to predict coronary heart disease

Targeting high-density lipoprotein cholesterol in diabetic patients to reduce cardiovascular risk

Bridging the gap in treatment options for patients with hypertriglyceridemia

Peer review (1 review for 1 publication/grant)